Company Description
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.
It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.
The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.
Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Oct 30, 2013 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 815 |
| CEO | Marc A. Stapley |
Contact Details
Address: 6000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
| Phone | (650) 243-6300 |
| Website | veracyte.com |
Stock Details
| Ticker Symbol | VCYT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001384101 |
| CUSIP Number | 92337F107 |
| ISIN Number | US92337F1075 |
| Employer ID | 20-5455398 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Marc A. Stapley | Chief Executive Officer and Director |
| Rebecca Chambers | Executive Vice President and Chief Financial Officer |
| Annie McGuire | Executive Vice President, General Counsel and Chief People Officer |
| Jonathan Wygant | Vice President and Chief Accounting Officer |
| Steven French | Senior Vice President and Chief Information Officer |
| Dr. Phillip G. Febbo M.D. | Chief Scientific and Medical Officer |
| Karen Possemato | Senior Vice President of Corporate Marketing, Communications and Commercial Operations |
| Robert Brainin | Executive Vice President and Chief Business Officer |
| Dr. John Leite Ph.D. | Chief Commercial Officer for CLIA Business |
| Corinne Danan | Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K/A | [Amend] Current report |
| Apr 1, 2024 | 144 | Filing |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 424B7 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 424B7 | Filing |
| Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 29, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 29, 2024 | 10-K | Annual Report |